
Michael Flanagan, PhD, on Del-zota’s Breakthrough Potential for Duchenne Muscular Dystrophy
The treatment landscape for Duchenne muscular dystrophy (DMD) is rapidly evolving, driven by advances in gene therapy, exon skipping, and steroid-sparing strategies. While corticosteroids have long served as the mainstay of care, newer therapies, like Del- …